Monitor the full data presentation at AACR in April 2026 for deeper insights into durability and immune response; consider positioning ahead of potential partnership or trial expansion announcements.
Price Chart
Executive Summary
Beyond Cancer, Ltd., a subsidiary of Beyond Air (XAIR), announced early clinical activity and a favorable safety profile from a Phase 1 trial of ultra-high concentration nitric oxide (UNO) therapy in heavily pretreated cancer patients. Seven of ten patients remain alive 19–37 months after a single UNO injection, with two triple-negative breast cancer patients showing no evidence of disease. Data will be presented at the AACR Annual Meeting in April 2026.
Key Facts
- Phase 1 trial (NCT05351502) evaluated intratumoral UNO in 10 heavily pretreated patients with solid tumors.
- Seven of ten patients remain alive 19–37 months post-treatment; one died of disease progression at 25 months.
- Two triple-negative breast cancer patients have no evidence of disease after single UNO injection.
- Favorable safety profile: most adverse events were Grade 1; one non-dose-limiting serious event (hypoxia) at 25,000 ppm.
- Data to be presented at AACR Annual Meeting 2026 on April 19, 2026, including updated analysis beyond the abstract.
Financial Impact
Potential long-term value creation if UNO demonstrates efficacy in larger trials; no immediate revenue impact.
Risk Factors
- Early-phase data from only 10 patients; larger trials needed to confirm efficacy.
- No guarantee of regulatory approval or commercial viability despite promising early results.
- Company has low market cap ($9M), indicating high risk and potential volatility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257691 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | SC 13G/A | $2.34 | awaiting T+60 | — | $2.14 (−8.55%) |
Oct 8, 2026 18d ago | 8-K | $2.31 | awaiting T+60 | — | $2.14 (−7.36%) |
Sep 24, 2026 4w ago | 8-K | $2.85 | awaiting T+60 | — | $2.14 (−24.91%) |
Aug 25, 2026 8w ago | EFFECT | $4.98 | awaiting T+60 | — | $2.14 (+57.03%) |
Jul 31, 2026 12w ago | Insider Cluster | $6.33 | awaiting T+60 | — | $2.14 (−66.19%) |
Jul 31, 2026 12w ago | 8-K | $5.28 $2.14 | ▲ +59.43% | ▲ +61.89% | $2.14 (+59.43%) |
Jul 2, 2026 16w ago | Court Ruling | $0.4390 $0.1415 | ▲ +67.77% | ▲ +69.49% | $2.14 (−387.47%) |
Jun 26, 2026 17w ago | 8-K | $0.4646 $0.1505 | ▼ −67.61% | ▼ −71.22% | $2.14 (+360.61%) |
Jun 22, 2026 18w ago | 8-K | $0.4680 $0.1540 | ▼ −67.09% | ▼ −71.05% | $2.14 (+357.26%) |
Apr 20, 2026 27w ago | Press Release | $10.90 $5.55 | ▼ −49.08% | ▼ −55.28% | $2.14 (−80.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers